Page last updated: 2024-08-17

cytidine and 2019 Novel Coronavirus Disease

cytidine has been researched along with 2019 Novel Coronavirus Disease in 75 studies

Research

Studies (75)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	75 (100.00)	2.80

Authors

Authors	Studies
Cherrington, NJ; Ekins, S; McGrath, ME; Miller, SR; Wright, SH; Zorn, KM	1
Amara, A; Else, L; FitzGerald, R; Fletcher, T; Hale, C; Khoo, S; Lyons, R; Penchala, SD; Walker, L	1
Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X	1
Tsanni, A	1
Couzin-Frankel, J	1
Khan, L; Mabood, N; Maqbool, M; Ullah, A; Ullah, M	1
Dybul, M; Kazatchkine, M; Legido-Quigley, H; Liu, J; Mabuchi, S; Matsoso, P; Nordström, A; Phelan, A; Ramchandani, R; Singh, S; Sudan, P	1
He, G; Huang, W; Zhao, Y	1
Hamblin, MR; Hashemian, SMR; Mirzaei, H; Pourhanifeh, MH; Shahrzad, MK	1
Whitley, R	1
Assaid, C; Brown, ML; Butterton, JR; Caraco, Y; De Anda, C; Delos Reyes, V; Du, J; Gomes da Silva, MM; Gonzalez, A; Grobler, JA; Jayk Bernal, A; Johnson, MG; Kovalchuk, E; Martín-Quirós, A; Musungaie, DB; Paschke, A; Pedley, A; Shamsuddin, HH; Strizki, J; Tipping, R; Wan, H; Williams-Diaz, A	1
Baden, LR; Morrissey, S; Rubin, EJ	1
Alabanza, P; Azizad, MM; Baric, R; Borroto-Esoda, K; Cohen, MS; Coombs, RW; Duke, ER; Eron, JJ; Fang, L; Fischer, WA; Holman, W; James Loftis, A; Lipansky, F; Mollan, KR; Painter, WP; Sheahan, TP; Szewczyk, LJ; Wohl, DA; Wolfe, CR	1
Pourkarim, F; Pourtaghi-Anvarian, S; Rezaee, H	1
Jaeschke, R; Mrukowicz, J; Rochwerg, B	1
Borio, LL; Bright, RA; Emanuel, EJ	1
Misra, A; Singh, A; Singh, AK; Singh, R	1
Bruno, MJ; de Vries, AC; Haagmans, BL; Lamers, MM; Lavrijsen, M; Li, P; Pan, Q; Peppelenbosch, MP; Rottier, RJ; Wang, Y	1
Kozlov, M	1
Bajaj, SS; Stanford, FC	1
Schinazi, RF; Swanstrom, R	1
Amran, M; Arancon, D; Arkell, P; Chekmeneva, E; Cooke, GS; Haber, A; Hammond, R; Jackson, H; Kaforou, M; Lewis, MR; Li, HK; Mehta, R; Mills, E; Noursadeghi, M; Rawson, TM; Sands, C; Sriskandan, S; Takats, Z	1
Babashkina, MG; Burkhanova, TM; Safin, DA; Sharov, AV; Taskın Tok, T	1
Ledford, H	1
Brophy, JM	1
Mills, E; Sheldrick, K; Thorlund, K	1
Abellon-Ruiz, J; Selvi-Sabater, P	1
Levenstein, S	1
Hulstaert, F; Jespers, V; Roberfroid, D	1
De Anda, C; Johnson, MG; Pedley, A	1
Sacks, HS	1
Extance, A	1
Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H	1
Azar, MM; Cohen, E; Malinis, M; Palacios, CF; Radcliffe, C	1
Azeem, S; Cheema, HA; Fatima, M; Saeed, J; Shahid, A	1
Bassetti, M; Bhagani, S; Brown, ML; Burgess, L; De Anda, C; Duke, ER; Ghosn, J; Johnson, MG; Moncada, PA; Ohmagari, N; Paschke, A; Puenpatom, A; Wan, H; Williams-Diaz, A; Wolf, T; Zhang, Y	1
Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Yan, Y; Yang, X; Zhong, W	1
Alsumali, A; Briggs, A; Cohen, J; Duke, ER; Goswami, H; Jiang, Y; Puenpatom, A; Schindler, M	1
Mahase, E	1
Aihara, H; Harki, DA; Moeller, NH; Passow, KT	1
Bearne, SL; Gillis, TD	1
Kolli, D; Ramakrishna, DS; Seelama, NV; Venkatanarayana, P	1
Beasley, DW; Brasel, T; Comer, JE; Garron, T; Grimes, M; Johnson, DM; Massey, S; Smith, J; Torres, M; Villasante-Tezanos, A; Wallace, S	1
Wise, J	1
Chuang, MH; Hsu, WH; Lai, CC; Liu, TH; Shiau, BW; Tsai, YW; Wu, JY	1
Dhand, A; Kapur, R; Nishida, S; Ohira, S; Okumura, K; Wolfe, K	1
Arvanitis, P; Farmakiotis, D; Guermazi, D	1
Birger, R; Cao, Y; Chawla, A; De Anda, C; Maas, BM; Paschke, A; Rizk, ML; Stone, JA; Wan, H	1
Khoi Quan, N; Linh, NNH; Nguyen, D; Tao, NPH; Tien Huy, N; Tran, NH; Tran, VP	1
Huang, PY; Lai, CC; Liu, TH; Tsai, YW; Wu, JY	1
Huang, C	1
Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P	1
Donovan-Banfield, I; Hartman, H; Hisner, R; Løchen, A; Peacock, TP; Ruis, C; Sanderson, T	1
Baik, SH; Baye, F; Fung, KW; McDonald, CJ	1
Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S	1
Andreou, A; Filippou, D; Sipsas, N; Trantza, S; Tsiodras, S	1
Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P	1
Shilatifard, A	1
Govil, A; Luckett, K; Miller-Handley, H	1
Askin, FB; Baric, RS; Bluemling, GR; Browne, EP; De, C; Dinnon, KH; Garcia, JV; Gralinski, LE; Grant, PO; Gully, K; Johnson, CE; Jones, CD; Kolykhalov, AA; Kovarova, M; Krzystek, HM; Leist, SR; Liu, H; Madden, VJ; Natchus, MG; Painter, G; Pickles, RJ; Schäfer, A; Wahl, A; White, KK; Yao, W; Zaman, T	1
Dolgin, E	1
Barbian, K; Bosio, CM; Feldmann, F; Feldmann, H; Haddock, E; Hansen, F; Hawman, DW; Jarvis, MA; Leventhal, S; Martens, C; Meade-White, K; Okumura, A; Ricotta, E; Rosenke, K; Rosenke, R; Saturday, G; Schwarz, B	1
Reina, J	1
Gordon, CJ; Götte, M; Schinazi, RF; Tchesnokov, EP	1
Ansari, MA; Simmonds, P	1
Bakowski, MA; Beutler, N; Burton, DR; Chatterjee, AK; Chen, E; Chi, V; Das, S; Fuller, M; Garcia, E; Ghosh, P; Gupta, AK; Huang, E; Hull, MV; Joseph, SB; Kirkpatrick, MG; Kuo, P; McNamara, CW; Nguyen, TH; Pan, K; Parren, M; Ricketts, J; Riva, L; Roberts, AJ; Rogers, TF; Sahoo, D; Schultz, PG; Shaabani, N; Teijaro, JR; Vargas, N; Wolff, KC; Woods, AK; Yang, L	1
Menéndez-Arias, L	1
Alexander, LEC; Behroozikhah, M; Beutler, N; Burton, DR; Castillo, V; Claire, A; Crotty, S; Dan, JM; Das, S; Duran, J; Fuller, M; Ghosh, P; Katkar, GD; Khandelwal, S; Pretorius, V; Ramirez, SI; Rawlings, SA; Rogers, TF; Sahoo, D; Smith, DM; Taheri, S; Tindle, C	1
Abdelnabi, R; De Jonghe, S; Foo, CS; Maes, P; Neyts, J; Weynand, B	1
Cramer, P; Dienemann, C; Hillen, HS; Höbartner, C; Kabinger, F; Kokic, G; Schmitzová, J; Stiller, C	1
Bush, J; Cohen, O; Holman, W; McIntosh, S; Painter, G; Painter, W	1

Reviews

9 review(s) available for cytidine and 2019 Novel Coronavirus Disease

Article	Year
Cytidine deamination-induced perpetual immunity to SAR-CoV-2 infection is a potential new therapeutic target. International journal of medical sciences, 2021, Volume: 18, Issue:16 Topics: COVID-19; Cytidine; Cytidine Deaminase; Deamination; Humans; Immunity; SARS-CoV-2; Vaccination	2021
RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 146 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; RNA-Dependent RNA Polymerase	2022
Molnupiravir: A new candidate for COVID-19 treatment. Pharmacology research & perspectives, 2022, Volume: 10, Issue:1 Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Interactions; Humans; Hydroxylamines; SARS-CoV-2	2022
Response to the letter to the editor on "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials". Journal of medical virology, 2023, Volume: 95, Issue:7 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome	2023
Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023; 95: e28621. Journal of medical virology, 2023, Volume: 95, Issue:7 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome	2023
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. In vivo (Athens, Greece), 2020, Volume: 34, Issue:3 Suppl Topics: Acetylcysteine; Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Betacoronavirus; Colchicine; Copper; Coronavirus Infections; COVID-19; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Inflammation; Nitric Oxide; Pandemics; Pneumonia, Viral; Prodrugs; Ribonucleosides; SARS-CoV-2; Virus Internalization; Virus Replication	2020
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular cell, 2020, 09-03, Volume: 79, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication	2020
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Advances in chronic kidney disease, 2020, Volume: 27, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2	2020
[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021, Volume: 34, Issue:5 Topics: Animals; Antiviral Agents; COVID-19; Cytidine; Depsipeptides; Humans; Hydroxylamines; Peptide Elongation Factors; Peptides, Cyclic; Ribonucleosides; SARS-CoV-2	2021

Trials

6 trial(s) available for cytidine and 2019 Novel Coronavirus Disease

Article	Year
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 02-10, Volume: 386, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Viral Load; Young Adult	2022
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Science translational medicine, 2022, Jan-19, Volume: 14, Issue:628 Topics: Animals; Chlorocebus aethiops; COVID-19; Cytidine; Humans; Hydroxylamines; RNA, Viral; SARS-CoV-2; Treatment Outcome; Vero Cells	2022
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:2 Topics: Adenosine Monophosphate; Aged; Alanine; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Double-Blind Method; Drug Approval; Drug Combinations; Female; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Male; Middle Aged; Nitriles; Proline; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome	2022
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Annals of internal medicine, 2022, Volume: 175, Issue:8 Topics: Adult; Biomarkers; COVID-19; Cytidine; Double-Blind Method; Humans; Hydroxylamines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	2022
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:6 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2023
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials, 2021, Aug-23, Volume: 22, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Ribonucleosides; United States	2021

Other Studies

60 other study(ies) available for cytidine and 2019 Novel Coronavirus Disease

Article	Year
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. Molecular pharmacology, 2021, Volume: 100, Issue:6 Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Dose-Response Relationship, Drug; Drug Interactions; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; HeLa Cells; Humans; Protein Binding; SARS-CoV-2	2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. Journal of pharmaceutical and biomedical analysis, 2021, Nov-30, Volume: 206 Topics: Chromatography, Liquid; COVID-19; Cytidine; Humans; Hydroxylamines; Reproducibility of Results; Saliva; SARS-CoV-2; Tandem Mass Spectrometry	2021
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, Volume: 72 Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load	2021
Unmet need for COVID-19 therapies in community settings. The Lancet. Infectious diseases, 2021, Volume: 21, Issue:11 Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal; Antiviral Agents; Community Health Services; COVID-19; COVID-19 Vaccines; Cytidine; Drug Combinations; Health Services Needs and Demand; Humans; Hydroxylamines; Socioeconomic Factors; Treatment Outcome; Viral Load	2021
African scientists race to test COVID drugs - but face major hurdles. Nature, 2021, Volume: 599, Issue:7883 Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization	2021
Antiviral pills could change pandemic's course. Science (New York, N.Y.), 2021, Nov-12, Volume: 374, Issue:6569 Topics: Antiviral Agents; Clinical Trials as Topic; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Tablets	2021
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response. BMJ (Clinical research ed.), 2021, 11-28, Volume: 375 Topics: Antiviral Agents; Communicable Disease Control; COVID-19; COVID-19 Vaccines; Cytidine; Global Health; Health Policy; Health Services Accessibility; Humans; Hydroxylamines; Oxygen Inhalation Therapy; Pandemics; Public Health; SARS-CoV-2; World Health Organization	2021
A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe. Signal transduction and targeted therapy, 2021, 12-02, Volume: 6, Issue:1 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Mutation; RNA; SARS-CoV-2	2021
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19. The New England journal of medicine, 2022, 02-10, Volume: 386, Issue:6 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Audio Interview: A Potential New Agent to Treat Covid-19. The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Hospitalization; Humans; Hydroxylamines; Mutagenesis; Risk Assessment; SARS-CoV-2; Time-to-Treatment; Vaccine Efficacy; Viral Load; Virus Replication	2021
Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients? Polish archives of internal medicine, 2022, 01-28, Volume: 132, Issue:1 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Outpatients; SARS-CoV-2	2022
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics. JAMA, 2022, Jan-18, Volume: 327, Issue:3 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunization Schedule; Lactams; Leucine; Nitriles; Population Surveillance; Proline; Ritonavir; SARS-CoV-2; United States	2022
COVID is here to stay: countries must decide how to adapt. Nature, 2022, Volume: 601, Issue:7892 Topics: Adaptation, Psychological; Adult; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunity, Herd; Immunization, Secondary; International Cooperation; Lactams; Leucine; Nitriles; Physical Distancing; Proline; Reinfection; Ritonavir; SARS-CoV-2; Social Change; South Africa	2022
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell research, 2022, Volume: 32, Issue:3 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Why scientists are racing to develop more COVID antivirals. Nature, 2022, Volume: 601, Issue:7894 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Combinations; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Medication Adherence; Molecular Targeted Therapy; Mutagenesis; Nitriles; Proline; Public-Private Sector Partnerships; Research Personnel; Ritonavir; SARS-CoV-2	2022
COVID-19: LMICs need antivirals as well as vaccines. Nature, 2022, Volume: 602, Issue:7895 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline	2022
Lethal mutagenesis as an antiviral strategy. Science (New York, N.Y.), 2022, Feb-04, Volume: 375, Issue:6580 Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; DNA; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutagenicity Tests; Phosphorylation; Ribonucleosides; RNA Virus Infections; RNA Viruses; RNA, Viral; SARS-CoV-2	2022
Antiviral metabolite 3'-deoxy-3',4'-didehydro-cytidine is detectable in serum and identifies acute viral infections including COVID-19. Med (New York, N.Y.), 2022, Mar-11, Volume: 3, Issue:3 Topics: Antiviral Agents; Bacterial Infections; COVID-19; Cytidine; Humans; Virus Diseases	2022
Molnupiravir for treatment of COVID-19. The Medical letter on drugs and therapeutics, 2022, Jan-24, Volume: 64, Issue:1642 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Interactions; Humans; Hydroxylamines; Treatment Outcome; United States; United States Food and Drug Administration	2022
Treatment of COVID-19 in high-risk outpatients. The Medical letter on drugs and therapeutics, 2022, Feb-07, Volume: 64, Issue:1643 Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Proline; Ritonavir; Treatment Outcome	2022
Computational Analysis of Molnupiravir. International journal of molecular sciences, 2022, 01-28, Volume: 23, Issue:3 Topics: Antiviral Agents; Computational Biology; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Molecular Docking Simulation; Protein Binding; SARS-CoV-2	2022
Hundreds of COVID trials could provide a deluge of new drugs. Nature, 2022, Volume: 603, Issue:7899 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication	2022
Molnupiravir's authorisation was premature. BMJ (Clinical research ed.), 2022, 03-03, Volume: 376 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Humans; Hydroxylamines; SARS-CoV-2	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d. Annals of internal medicine, 2022, Volume: 175, Issue:4 Topics: Adult; COVID-19; Cytidine; Hospitalization; Humans; Hydroxylamines; SARS-CoV-2	2022
Covid-19: What is the evidence for the antiviral molnupiravir? BMJ (Clinical research ed.), 2022, 04-13, Volume: 377 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, Volume: 607, Issue:7917 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles	2022
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022, Volume: 22, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Testing; Cytidine; Female; Humans; Hydroxylamines; Male; Middle Aged; Organ Transplantation; Ritonavir; SARS-CoV-2; Transplant Recipients	2022
Efficacy and safety of molnupiravir for COVID-19 patients. European journal of internal medicine, 2022, Volume: 102 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses, 2022, 05-25, Volume: 14, Issue:6 Topics: Animals; Antigens, Viral; Antiviral Agents; Child, Preschool; COVID-19; Cytidine; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Humans; Hydroxylamines; Mice; Mice, Inbred ICR	2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. PharmacoEconomics, 2022, Volume: 40, Issue:7 Topics: Adult; Cost-Benefit Analysis; COVID-19; Cytidine; Humans; Hydroxylamines; Male; Outpatients; Prostate-Specific Antigen; Quality-Adjusted Life Years	2022
Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished. BMJ (Clinical research ed.), 2022, 08-19, Volume: 378 Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; India	2022
SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA. Viruses, 2022, 08-16, Volume: 14, Issue:8 Topics: Antiviral Agents; COVID-19; Cytidine; Exoribonucleases; Humans; Mutation; Nucleotides; RNA; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Viral Nonstructural Proteins; Virus Replication	2022
Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2. ChemMedChem, 2022, 12-05, Volume: 17, Issue:23 Topics: Antiviral Agents; COVID-19; Cytidine; Escherichia coli; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Vidarabine	2022
Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine. Nucleosides, nucleotides & nucleic acids, 2023, Volume: 42, Issue:6 Topics: Acylation; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2023
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model. Antiviral research, 2023, Volume: 209 Topics: Animals; COVID-19; Cytidine; Macaca mulatta; SARS-CoV-2	2023
Covid-19: Molnupiravir does not cut hospital admissions or deaths in vaccinated people at high risk, trial finds. BMJ (Clinical research ed.), 2022, 12-23, Volume: 379 Topics: Antiviral Agents; COVID-19; Cytidine; Hospitals; Humans; Hydroxylamines	2022
The effect of molnupiravir on post-acute outcome of COVID-19 survivors. The Journal of infection, 2023, Volume: 87, Issue:4 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2023
Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients. Transplantation, 2023, 06-01, Volume: 107, Issue:6 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Organ Transplantation; Transplant Recipients	2023
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept. Infection, 2023, Volume: 51, Issue:5 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Immunocompromised Host	2023
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries. Pathogens and global health, 2023, Volume: 117, Issue:6 Topics: Antiviral Agents; COVID-19; Cytidine; Developing Countries; Humans; Hydroxylamines	2023
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment. Molecular pharmaceutics, 2023, 09-04, Volume: 20, Issue:9 Topics: Animals; COVID-19; Cytidine; Hydroxylamines; Rats	2023
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature, 2023, Volume: 623, Issue:7987 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutation; Phylogeny; SARS-CoV-2; Viral Load; Virus Replication	2023
Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients. JAMA internal medicine, 2023, Dec-01, Volume: 183, Issue:12 Topics: Aged; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Lactams; Nitriles	2023
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science translational medicine, 2020, 04-29, Volume: 12, Issue:541 Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication	2020
COVID-19: Rescue by transcriptional inhibition. Science advances, 2020, Volume: 6, Issue:27 Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Humans; Hydroxylamines; Pandemics; Pneumonia, Viral; Ribonucleosides; RNA-Dependent RNA Polymerase; SARS-CoV-2; Transcription, Genetic	2020
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, Volume: 591, Issue:7850 Topics: Administration, Oral; Alveolar Epithelial Cells; Animals; Chemoprevention; Chiroptera; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Cytokines; Epithelial Cells; Female; Heterografts; Humans; Hydroxylamines; Immunity, Innate; Interferon Type I; Lung; Lung Transplantation; Male; Mice; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; SARS-CoV-2; Virus Replication	2021
The race for antiviral drugs to beat COVID - and the next pandemic. Nature, 2021, Volume: 592, Issue:7854 Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Birds; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Industry; Europe; Humans; Hydroxylamines; Indoles; Influenza, Human; Leucine; Orthomyxoviridae; Pandemics; Pyrrolidinones; Severe Acute Respiratory Syndrome; Strategic Stockpile; United States	2021
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature communications, 2021, 04-16, Volume: 12, Issue:1 Topics: Administration, Oral; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Humans; Hydroxylamines; Mesocricetus; SARS-CoV-2; Vero Cells; Virus Replication	2021
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. The Journal of biological chemistry, 2021, Volume: 297, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Mutagenesis; Point Mutation; RNA, Viral; SARS-CoV-2	2021
Extensive C->U transition biases in the genomes of a wide range of mammalian RNA viruses; potential associations with transcriptional mutations, damage- or host-mediated editing of viral RNA. PLoS pathogens, 2021, Volume: 17, Issue:6 Topics: Animals; APOBEC Deaminases; Base Sequence; COVID-19; Cytidine; DNA Damage; Evolution, Molecular; Gene Expression Regulation, Viral; Genome, Viral; Host-Pathogen Interactions; Humans; Mammals; Mutation; Nucleic Acid Conformation; Phylogeny; RNA Editing; RNA Viruses; RNA, Viral; SARS-CoV-2; Sequence Analysis, RNA; Transcription, Genetic; Uridine	2021
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nature communications, 2021, 06-03, Volume: 12, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; COVID-19; COVID-19 Drug Treatment; Cytidine; Databases, Pharmaceutical; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxylamines; Mesocricetus; Nelfinavir; Pandemics; SARS-CoV-2; Virus Replication	2021
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. The Journal of biological chemistry, 2021, Volume: 297, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Point Mutation; RNA, Viral; SARS-CoV-2	2021
AI-guided discovery of the invariant host response to viral pandemics. EBioMedicine, 2021, Volume: 68 Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antiviral Agents; Artificial Intelligence; Autopsy; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Databases, Genetic; Disease Models, Animal; Gene Expression Profiling; Gene Regulatory Networks; Genetic Markers; Humans; Hydroxylamines; Interleukin-15; Lung; Mesocricetus; Pandemics; Receptors, Interleukin-15; Virus Diseases	2021
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. The Journal of infectious diseases, 2021, 09-01, Volume: 224, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Disease Models, Animal; Female; Hydroxylamines; Mutation; Pandemics; SARS-CoV-2; Virus Replication	2021
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature structural & molecular biology, 2021, Volume: 28, Issue:9 Topics: Animals; Antiviral Agents; Base Sequence; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Models, Molecular; Molecular Structure; Mutagenesis; Mutation; Nucleic Acid Conformation; Protein Binding; Protein Conformation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication	2021